During 2023 we achieved profitability while intensively investing in the development of our late-stage assets and the scale-up of our commercial infrastructure and marketing activity. This has resulted in Telix capturing a meaningful market share in the growing urology imaging market whilst laying the foundation for our next commercial products.
We are continuing to accelerate the development of our theranostic pipeline and vertical integration of supply and manufacturing. This activity, which is key to diversifying our revenue streams, creates additional value for our therapeutic assets and further differentiates Telix as a fully integrated global radiopharmaceutical company.
Key financial metrics: Earnings accelerate development in late-stage assets
Operational highlights: Driving towards our next phase of value creation
Global revenue $496.2 million up 218% on 2022
U.S. indication expanded to include patient selection for PSMA-directed radioligand therapy
ProstACT SELECT positive interim readout
ProstACT GLOBAL dosing patients in Australia
TLX250-CDx (Zircaix™1) BLA submitted
Four clinical trials dosing patients
OPALESCENCE IIT2 in breast cancer, positive top-line data
IPAX-2 second patient cohort enrolled
IPAX-Linz IIT exceeds 70% recruitment
Preclinical proof-of-concept for radiolabelled olaratumab (TLX300)
Ethics application submitted for TLX300-CDx trial
Telix Manufacturing Solutions Stage 1 buildout complete
Optimal Tracers business integration and onboarding complete
Acquisition of Dedicaid GmbH
Acquisition of Lightpoint Medical's business
Strategic investment in Mauna Kea Technologies
Further detail on financial and operational performance can be found in the Our performance, strategy and future prospects section of this Report.
- Trade name subject to final regulatory approval.
- Investigator-initiated trial.